Helius Medical Technologies, Inc. Fulfills First U.S. Prescriptions for PoNS®
– First patients have purchased PoNS devices to initiate PoNS Therapy –– Nineteen PoNS device prescriptions have been written in the U.S. since recent commercial launch – NEWTOWN, Pa., April 27, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the fulfillment […]
Helius Medical Technologies, Inc. Introduces Device in U.S. To Help Multiple Sclerosis Patients Improve Walking Ability
– Breakthrough technology for MS patients helps patients with gait deficit – Portable Neuromodulation Stimulator (PoNS®) is an innovative non-surgical medical device that includes a controller and a mouthpiece – Available directly to patients by prescription, used in conjunction with physical therapy NEWTOWN, Pa., April 26, 2022 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq: […]
Helius Medical Technologies, Inc. Announces Issuance of U.S. Patent for Wireless PoNS®
Patent Readies Company for Next Generation of PoNS Therapy NEWTOWN, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (Helius or the Company), a neurotech company focused on neurological wellness, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,197,994, which is directed to systems […]
Helius Medical Technologies, Inc. Launches Therapeutic Experience Program; NYU Langone Health Is Initial Clinical Trial Site
– Multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis –– Program to include 10-12 U.S. Centers of Excellence; enrollment to commence in Q4 2021 – NEWTOWN, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the […]
Helius Medical, Inc. Receives U.S. Marketing Authorization for the PoNS™ Device
First and only tongue-delivered neuromodulation therapy provides new treatment option for U.S. patients living with gait deficit due to symptoms from multiple sclerosis NEWTOWN, Pa., March 29, 2021 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that its wholly owned subsidiary, […]
Helius Medical Technologies, Inc. Announces Formation of Multiple Sclerosis Scientific Advisory Board
Leading Multiple Sclerosis Experts to Inform U.S. Launch Planning and Market Access Strategies NEWTOWN, Pa., Oct. 08, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the formation of a Multiple Sclerosis (“MS”) Scientific Advisory Board. The Helius MS Scientific Advisory […]
Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis
NEWTOWN, Pa., May 12, 2020 (GLOBE NEWSWIRE) – Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that it has received Breakthrough Designation for its PoNS™ device as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis (“MS”), to be used as […]